XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.1
COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (64,851) $ (23,427)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 726 289
Stock-based compensation expense 6,901 1,117
Write-down of inventory 75 213
Write-off of other assets - related party 984  
Sales under sales type leases   (46)
Payments received on net investment in lease 10 2
Changes in assets and liabilities:    
Accounts receivable (379) (174)
Unbilled receivables (91)  
Inventory (2,667) (1,931)
Prepaid expenses and other current assets (666) 146
Due from related parties 1,451 (782)
Other assets - related party 260 226
Prepaid inventory   651
Other long term assets (1,201)  
Accounts payable 1,436 (377)
Deferred grant funding 1,052 1,610
Deferred revenue 1,082 158
Due to related parties 1,845 27
Accrued expenses and other current liabilities 6,851 773
Net cash used in operating activities (47,182) (21,525)
Cash flows from investing activities:    
Purchases of fixed assets (2,711) (1,568)
Net cash used in investing activities (2,711) (1,568)
Cash flows from financing activities:    
Proceeds from exercise of stock options 1,497 120
Proceeds from issuance of Series D convertible preferred stock 30,468 59,769
Stock issuance costs related to Series D convertible preferred stock (7) (129)
Proceeds from issuance of notes payable   1,067
Repayment of notes payable (178) (889)
Investment from 4Bionics, LLC 3,516 1,000
Net proceeds from equity infusion from the Business Combination 141,471  
Net cash provided by financing activities 176,767 60,938
Net increase in cash and cash equivalents and restricted cash 126,874 37,845
Cash, cash equivalents and restricted cash, beginning of year 64,286 26,441
Cash, cash equivalents and restricted cash, end of year 191,160 64,286
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position    
Cash and cash equivalents 188,498 62,676
Restricted cash 2,662 1,610
Total cash, cash equivalents and restricted cash 191,160 64,286
Supplemental disclosure of cash flow information:    
Cash received from exchange of research and development tax credits 374 261
Supplemental disclosure of noncash information:    
Noncash acquisition of fixed assets   $ 136
Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination $ 3,000